Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apyx MedicalFRA:BOV 72 1-Year ROIIC % is 167.14 as of Jun. 2026. GuruFocus rates FRA:BOV with a GF Score™ of 72/100 and a GF Value™ of €1.85. The stock has 2 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Apyx Medical ranks better than 88.88% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Apyx Medical's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was 167.14%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Apyx Medical's 1-Year ROIIC % or its related term are showing as below:
FRA:BOV's 1-Year ROIIC % is ranked better than 88.88% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.035
vs FRA:BOV: 167.14
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Apyx Medical 1-Year ROIIC % Related Terms
Apyx Medical 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Apyx Medical's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BOV vs INGN, QSI, QTRX: 1-Year ROIIC % Comparison
For the Medical Devices subindustry, Apyx Medical's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apyx Medical 1-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Apyx Medical's 1-Year ROIIC % falls into.
Apyx Medical's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -3.056 (Jun. 2026) - -11.24 (Jun. 2025) )
/
( 22.087 (Jun. 2026) - 17.513 (Jun. 2025) )
=
8.184
/
4.574
=
178.92%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Apyx Medical (FRA:BOV) has a 1-Year ROIIC % of 167.14 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Apyx Medical and its competitors. According to the industry distribution chart, Apyx Medical ranks #91 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 11.1%.
Is Apyx Medical's 1-Year ROIIC % too high?
Apyx Medical's current 1-Year ROIIC % is 167.14. The Medical Devices & Instruments industry median 1-Year ROIIC % is 2.04. Apyx Medical's value of 167.14 is 8113.3% above this industry median. Based on the distribution chart, Apyx Medical ranks #91 out of 818 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's 1-Year ROIIC % compare to INGN and QSI?
According to the Medical Devices & Instruments industry distribution chart, Apyx Medical ranks #91 out of 818 companies for 1-Year ROIIC %. This places Apyx Medical in the top 11% of its industry — outperforming the majority of peers. The industry median 1-Year ROIIC % is 2.04. Apyx Medical's value of 167.14 is 8113.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Devices & Instruments company?
The median 1-Year ROIIC % among Medical Devices & Instruments companies is 2.04, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apyx Medical's current 1-Year ROIIC % of 167.14 is 8113.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Apyx Medical and its competitors. For the Medical Devices & Instruments industry, the median 1-Year ROIIC % is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apyx Medical's current 1-Year ROIIC % is 167.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current 1-Year ROIIC % of 167.14. The stock's GF Value™ is €1.85, compared to a current price of €2.56 — trading 38.4% above its estimated fair value. The current 1-Year ROIIC % is 167.14 and 8113.3% above the Medical Devices & Instruments industry median of 2.04. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current 1-Year ROIIC % is 167.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (FRA:BOV) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of €2.56 is trading 38.4% above its estimated GF Value™ of €1.85.
Key valuation signals for FRA:BOV:
1-Year ROIIC %: 167.14
GF Value™: €1.85 vs. price of €2.56 (38.4% above fair value)
Industry Position: 8113.3% above the Medical Devices & Instruments median (#91 of 818)
No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for FRA:BOV
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BOV has been successfully added to your 
